Every 10-Q that Urogen Pharma (URGN) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-Q covers the quarterly report filed between annual reports, so if you follow URGN and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full URGN filings page.
UroGen Pharma reported sharply higher oncology product sales for the quarter ended June 30, 2026. Net revenue reached $72.5 million, up from $24.2 million a year earlier, driven by Zusduri ($50.4 million) alongside Jelmyto ($22.0 million). Gross profit increased to $65.9 million, and operating results swung to a small income of $0.1 million from a $41.4 million loss. After interest, financing costs and income taxes, net loss narrowed to $14.4 million (loss per share $0.28) versus $49.9 million (loss per share $1.05). For the first half of 2026, revenue was $123.4 million with a net loss of $37.9 million.
At June 30, 2026, UroGen held cash, cash equivalents and marketable securities totaling $108.0 million, plus accounts receivable of $88.8 million, against total liabilities of $385.0 million. Key obligations include a prepaid forward liability of $125.1 million tied to Jelmyto and Zusduri sales and long-term debt of $188.7 million under a Pharmakon term loan maturing in 2030–2031. Shareholders’ deficit was $132.4 million on an accumulated deficit of $997.6 million.
Net cash used in operating activities was $78.3 million for the first six months of 2026. Management states that existing cash and marketable securities are expected to fund operations for more than one year, with future performance heavily dependent on commercialization of Jelmyto and Zusduri.
UroGen Pharma Ltd. reported first-quarter 2026 revenue of $50.9 million, significantly higher than the same period in 2025, driven by sales of Jelmyto and the newly approved bladder cancer drug Zusduri. Jelmyto contributed $21.7 million and Zusduri $29.2 million in product sales.
The company posted a net loss of $23.6 million, narrower than the prior-year period, as higher gross profit was partly offset by increased selling, general and administrative spending to support commercialization. Cash, cash equivalents and marketable securities totaled $140.3 million as of March 31, 2026, while long-term debt rose to $189.5 million after closing a new $200 million term loan with Pharmakon that refinanced existing borrowings and added liquidity.
UroGen also carries a prepaid forward obligation of $128.2 million tied to future Jelmyto and Zusduri net sales. Despite an accumulated deficit of $983.3 million, management believes current cash and investments can fund operations beyond one year, assuming continued uptake of its approved products.
UroGen Pharma (URGN) reported Q3 2025 results with revenue of $27,482 thousand, up from $25,204 thousand a year ago, as Jelmyto sales remained the primary driver and newly approved Zusduri contributed initial sales. Gross profit was $24,204 thousand. Operating expenses rose, led by selling, general and administrative costs of $37,582 thousand and research and development of $14,008 thousand, resulting in an operating loss of $27,386 thousand.
Net loss was $33,347 thousand (basic and diluted loss per share of $0.69). For the nine months, revenue reached $71,951 thousand with a net loss of $127,130 thousand. Cash, cash equivalents and marketable securities totaled $127.4 million as of September 30, 2025. The balance sheet reflected a prepaid forward obligation of $126,067 thousand and long‑term debt of $122,111 thousand. Shareholders’ deficit was $115,408 thousand.
Zusduri received FDA approval on June 12, 2025 and generated $1,779 thousand in Q3 sales, while Jelmyto delivered $25,703 thousand. Management stated that available cash and securities are expected to fund operations beyond one year from issuance. The company revised Q3 2024 loss per share to include 3,679,400 pre‑funded warrants in the weighted average shares outstanding.